Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07637071

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in men with androgenic alopecia.

The main aims of this trial are:

1. To confirm using photographic analysis, changes in the quality, volume, and thickness of hair. 2. To gauge patient satisfaction with hair changes and application process. 3. Monitor and report any adverse events associated with the daily intake of Xtressé

Participants who qualify will complete 3 visits after voluntary consent has been given. Participants will be given a 90-day supply of the gummies at visits 1 and 2 to cover the 6-month study period. Photographs and scalp analysis will be performed at each visit to measure changes in hair volume, thickness, and growth.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Advanced Dermatology & Cosmetic Surgery, Maitland, Florida, United States

Loading trial locations.

About this study

In the study, participants will be asked to complete the following:

Provide basic personal information (including date of birth, gender, race and ethnicity) Provide their medical/ surgical history and perform a medical exam (including but not limited to symptom-directed physical exam, skin type, vital signs, height, weight) Follow study rules such as avoiding certain medications and treatments Provide information on any medications, treatments or reactions that started after the study began Take gummy treatment daily and complete a treatment diary Allow clinical assessments and documentation of the treatment, such as photography, hair density measurements, any reactions or side effects

To qualify for this trial, participants must:

Be a male adult between 18 to 65 years of age Have hair loss in vertex region. Give voluntary written consent Be willing to follow study instructions and complete study requirements, including maintaining current diet and hair care routine, not using non-approved lotions and creams on the treatments areas Allow photographs of the front and top area of the scalp Confirm they are not sensitive to any of the study treatment ingredients

All photographs of the treatment area collected during the study will be used as study data.

All participants have the right to refuse further participation in the study at any time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males aged 18-65
  • Norwood III to IV, vertex focused
  • Fitzpatrick skin type I to VI
  • Ability and willingness to comply with study protocol

Exclusion criteria

  • Change in other hair treatments in 3 months prior to study enrollment.
  • Known uncontrolled health conditions.
  • History of hair or scalp disorders that could interfere with study results.
  • History of metabolic syndrome.

Treatment and study plan

Xtressé Hair Growth Gummies

Other

The nutraceutical supplement is powered by proprietary X-3 BioActive Blend and contains plant based extracts and regenerative compounds not commonly found in existing hair supplements. The dosage is 2 gummies taken once per day.

Primary outcomes

  1. Within-subject increase in hair density assessed via Canfield HairMetrix® Phototrichogram Analysis

    Time frame: From enrollment to the end of treatment at 6 months

    Quantitative hair measurements calculated by analyzing the participants digital images from baseline to 6 months of taking Xtressé™ Supplements. Measurements of density as measured hair per cm².

  2. Within-subject increase in hair thickness assessed via Canfield HairMetrix® Phototrichogram Analysis

    Time frame: From enrollment to the end of treatment at 6 months

    Quantitative hair measurements calculated by analyzing the participants digital images from baseline to 6 months of taking Xtressé™ Supplements. Measurements of follicular unit vellus/terminal ratio.

  3. Hair Density Changes measured by SOCAi

    Time frame: From enrollment to the end of treatment at 6 months

    Images will be captured using the the SOCAi system at baseline and Days 90, and 180, to evaluate hair density changes.

Secondary outcomes

  1. Incidence of Adverse Events associated with Treatment

    Time frame: From first treatment until the end of treatment at 6 months

    Collect and quantify the incidence of treatment-related adverse events and treatment-related serious adverse events associated with the daily intake of supplement

Other outcomes

  1. Participant self-assessment of hair improvements collected via questionnaire

    Time frame: From enrollment to the end of study at 6 months

    Observations and changes in hair loss graded on scale of 0 to 4 with 0 as no change and 4 as a very severe outcome. Observations are based on self-assessments completed at baseline and Day 180.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Matt Leavitt, DO

CONTACT

[email protected]

321-594-6851

Sponsors and collaborators

Lead sponsor

Restore Biologics Holdings, Inc. dba Xtressé

Industry

Registry information

Official study title

Pilot Study to Evaluate the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Men With Androgenic Alopecia

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 9, 2026
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.